<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04469062</url>
  </required_header>
  <id_info>
    <org_study_id>16825</org_study_id>
    <secondary_id>I6T-MC-AMBI</secondary_id>
    <secondary_id>2019-001653-99</secondary_id>
    <nct_id>NCT04469062</nct_id>
  </id_info>
  <brief_title>A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis</brief_title>
  <acronym>LUCENT-ACT</acronym>
  <official_title>A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and Active- Controlled Treat-Through Study of Mirikizumab and Vedolizumab in Participants With Moderately to Severely Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if study drug mirikizumab is safe and effective
      compared to vedolizumab and placebo in participants with moderately to severely active
      ulcerative colitis (UC).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 20, 2021</start_date>
  <completion_date type="Anticipated">June 6, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 13, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants in Histologic Remission</measure>
    <time_frame>Week 12</time_frame>
    <description>Histologic remission based on histology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Symptomatic Remission</measure>
    <time_frame>Week 52</time_frame>
    <description>Symptomatic remission based on modified Mayo Score (MMS) stool frequency (SF) and rectal bleeding (RB) subscores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Clinical Remission</measure>
    <time_frame>Week 52</time_frame>
    <description>Clinical remission based on MMS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Endoscopic Remission</measure>
    <time_frame>Week 52</time_frame>
    <description>Endoscopic remission based on MMS ES.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Clinical Response</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinical response based on MMS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Corticosteroid (CS) Free Remission without Surgery (Subgroup of Participants on CS at Baseline)</measure>
    <time_frame>Week 52</time_frame>
    <description>CS free remission without surgery based on clinical remission, symptomatic remission and no CS use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Resolution of Extraintestinal Manifestations (EIMs) Among Those That had Them at Baseline</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of participants with resolution of EIMs among those that had them at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the Inflammatory Bowel Disease Questionnaire (IBDQ) Score</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from baseline on the IBDQ score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Undergoing Surgery for UC (Including Colectomy)</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of participants undergoing surgery for UC (including colectomy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Hospitalized for UC</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of participants hospitalized for UC.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Mirikizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirikizumab administered intravenously (IV) and subcutaneously (SC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vedolizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vedolizumab administered IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC and IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirikizumab IV</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Mirikizumab</arm_group_label>
    <other_name>LY3074828</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirikizumab SC</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Mirikizumab</arm_group_label>
    <other_name>LY3074828</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vedolizumab IV</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Vedolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo IV</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo SC</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have a diagnosis of UC for at least 3 months prior to baseline

          -  Participants must have a confirmed diagnosis of moderately or severely active UC, as
             assessed by the modified Mayo score (MMS)

          -  Participants must have demonstrated an inadequate response to, a loss of response to,
             or an intolerance to conventional or to biologic therapy for UC

          -  Participants must, if female, meet the contraception requirements

        Exclusion Criteria:

          -  Participants must not have a current diagnosis of Crohn's disease or inflammatory
             bowel disease-unclassified (indeterminate colitis)

          -  Participants must not have had a previous colectomy

          -  Participants must not have current evidence of toxic megacolon

          -  Participants must not have prior exposure to anti-IL-23p19 antibodies (e.g.
             risankizumab, brazikumab, guselkumab or tildrakizumab), vedolizumab, or natalizumab

          -  Participants must not have prior clinical failure or intolerance to anti-IL12p40
             antibodies (e.g. ustekinumab), anti-integrin antibodies other than vedolizumab and
             natalizumab (e.g. etrolizumab) or anti-integrin ligand antibodies (e.g. ontamalimab)
             within 4 weeks prior to screening endoscopy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>Clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/2CU7GWC1qkMxLL0Qo3HP8a?conditionId=nQ3Pakt8Ag4qwOawqiSQW</url>
    <description>A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis (LUCENT-ACT)</description>
  </link>
  <verification_date>July 15, 2020</verification_date>
  <study_first_submitted>July 10, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interleukin-23 (IL-23) antibody</keyword>
  <keyword>IL-23p19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vedolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

